2023
Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis
Meza L, Zengin Z, Salgia S, Malhotra J, Karczewska E, Dorff T, Tripathi A, Ely J, Kelley E, Mead H, Hsu J, Dizman N, Salgia N, Chawla N, Chehrazi-Raffle A, Muddasani R, Govindarajan A, Rock A, Liu S, Salgia R, Trent J, Altin J, Pal S. Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis. The Oncologist 2023, 28: e748-e755. PMID: 36971500, PMCID: PMC10485287, DOI: 10.1093/oncolo/oyad067.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccinationGenitourinary cancersRenal cell carcinomaBooster doseCell carcinomaImmune responseBlood samplesSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2T-cell receptor sequencingRespiratory syndrome coronavirus 2Baseline blood samplesMajority of patientsMinority of patientsProspective cohort analysisSyndrome coronavirus 2Twelve-month followAntibody titer analysisCOVID-19 vaccineSeroconversion ratesMedian ageUrothelial cancerCoronavirus 2Prostate cancerCohort analysisPerceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study
Castro D, Zengin Z, Malhotra J, Bergerot C, Meza L, Dizman N, Govindarajan A, Hsu J, Chehrazi-Raffle A, Chawla N, Mercier B, Chen S, Feng M, Prajapati S, Lee K, Philip E, Dorff T, Lyou Y, Pal S. Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study. Cancer Investigation 2023, 41: 70-76. PMID: 36239609, DOI: 10.1080/07357907.2022.2136683.Peer-Reviewed Original Research
2022
Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies.
Zengin Z, Meza L, Malhotra J, Salgia S, Ely J, Hsu J, Kelley E, Mead H, Dizman N, Chehrazi-Raffle A, Govindarajan A, Muddasani R, Chawla N, Dorff T, Lyou Y, Karczewska E, Trent J, Salgia R, Altin J, Pal S. Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies. Journal Of Clinical Oncology 2022, 40: 185-185. DOI: 10.1200/jco.2022.40.6_suppl.185.Peer-Reviewed Original ResearchCOVID-19 vaccinationBlood samplesSystemic treatmentAntibody titersGenitourinary malignanciesSubset of ptsImmune checkpoint inhibitorsBaseline blood samplesLong-term efficacyAdditional blood samplesCOVID-19 vaccineSARS-CoV-2Short-term effectivenessCancer ptsSerologic outcomeCheckpoint inhibitorsGenitourinary cancersMedian ageTherapy cyclesBladder cancerTCR sequencingIgG ELISACoV-2Host immunityVaccination